Keywords: Sanofi, Multaq, USA, FDA, Label warning, Aubagio, Multiple sclerosis, MS

FDA strengthens warnings on Sanofi’s Multaq; Aubagio disappoints

Article | 20 December 2011

Print This

The US Food and Drug Administration (FDA) has completed a safety review of French drug major Sanofi’s (Euronext: ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in